Journal of Cataract & Refractive Surgery
Volume 34, Issue 6 , Pages 897-901, June 2008

Plasminogen activator inhibitor in human tears after laser refractive surgery

From the Departments of Ophthalmology (Csutak, Silver, Steiber, Hassan, Berta) and Biochemistry and Molecular Biology (Tőzsér, Bagossi), University of Debrecen, Medical and Health Science Center, Faculty of Medicine, Debrecen, Hungary; and the Applied Physics Laboratory (Silver), Johns Hopkins University, Laurel, Maryland, USA

Accepted 27 February 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Drs. Csutak, Silver, Tőzsér, and Berta are co-inventors of a patent describing the use of urokinase-type plasminogen activator to prevent haze after laser vision correction surgery. No other author has a financial or proprietary interest in any material or method mentioned.

 Supported in part by the Hungarian Scientific Research Fund, OTKA grants T38351 and F49055, and Hungarian Eötvös grant 9/2004, Hungary.

 Szilvia Pető, University of Debrecen, Medical and Health Science Center, Faculty of Medicine, provided technical assistance.

PII: S0886-3350(08)00294-0

doi:10.1016/j.jcrs.2008.02.024

Journal of Cataract & Refractive Surgery
Volume 34, Issue 6 , Pages 897-901, June 2008

Article Tools

* Image Usage & Resolution